Earlier this month, the FDA approved ARS Pharmaceuticals Inc’s SPRY neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), for adult and pediatric patients.ARS Pharma’s Neffy is to be an alternative to EpiPen and other autoinjectors like Sanofi SA’s SNY Auvi-Q filled with epinephrine.Also Read: Allergic Reaction Focused ARS Pharmaceuticals’ Lead Candidate Shows Efficacy In Skin Disorder.Cantor Fitzgerald initiated ...